NasdaqGS - Delayed Quote USD

Royalty Pharma plc (RPRX)

28.38 +0.29 (+1.03%)
At close: May 13 at 4:00 PM EDT
28.38 0.00 (0.00%)
After hours: May 13 at 6:13 PM EDT

Key Executives

Amounts are as of December 31, 2023 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.
NameTitlePayExercisedYear Born
Mr. Pablo Gerardo Legorreta Founder, Chairman of the Board & CEO -- -- 1965
Mr. Terrance P. Coyne Executive VP & CFO 4.56M -- --
Mr. George Wingate Lloyd Executive VP of Investments & Chief Legal Officer 4.56M -- 1960
Mr. Christopher Hite Vice Chairman & Executive VP 4.56M -- 1968
Dr. Marshall Jonathan Urist M.D., Ph.D. Executive Vice President of Research & Investments 4.56M -- 1976
Mr. Arthur Richard McGivern J.D. Executive Vice President of Investments & General Counsel -- -- --
Mr. Ashwin Pai M.D. Executive Vice President of Investments -- -- --
Ms. Kristin Stafford Senior VP & Chief Accounting Officer -- -- 1982
Mr. Eric Cornelius Schneider Senior VP & Chief Technology Officer -- -- --
Dr. James Folmar Reddoch Ph.D. Executive VP of Investments & Chief Scientific Officer 3.4M -- 1970

Royalty Pharma plc

110 East 59th Street
New York, NY 10022
United States
212 883 0200 https://www.royaltypharma.com
Sector: 
Healthcare
Industry: 
Biotechnology

Description

Royalty Pharma plc operates as a buyer of biopharmaceutical royalties and a funder of innovations in the biopharmaceutical industry in the United States. It is also involved in the identification, evaluation, and acquisition of royalties on various biopharmaceutical therapies. In addition, the company collaborates with innovators from academic institutions, research hospitals and not-for-profits, small and mid-cap biotechnology companies, and pharmaceutical companies. Its portfolio consists of royalties on approximately 35 commercial products and 14 development-stage product candidates that address various therapeutic areas, such as rare disease, cancer, neuroscience, immunology, respiratory, infectious disease, hematology, and diabetes. The company was founded in 1996 and is based in New York, New York.

Corporate Governance

Royalty Pharma plc’s ISS Governance QualityScore as of May 1, 2024 is 5. The pillar scores are Audit: 6; Board: 5; Shareholder Rights: 6; Compensation: 3.
Corporate governance scores courtesy of Institutional Shareholder Services (ISS) Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.

Recent Events

Upcoming Events

Aug 06, 2024 - Aug 12, 2024
Royalty Pharma plc Earnings Call

Jun 14, 2024

Dividend Date

May 16, 2024

Ex-Dividend Date

Related Tickers

CYTK Cytokinetics, Incorporated
57.89
-6.78%
 
BBIO BridgeBio Pharma, Inc.
28.50
-2.06%
 
ARGX argenx SE
359.48
-4.04%
 
ROIV Roivant Sciences Ltd.
11.18
+0.45%
 
LEGN Legend Biotech Corporation
42.97
-0.62%
 
HALO Halozyme Therapeutics, Inc.
43.61
+1.07%
 
SPRO Spero Therapeutics, Inc.
1.6500
+0.61%
 
IONS Ionis Pharmaceuticals, Inc.
38.80
-0.72%
 
INCY Incyte Corporation
57.60
+8.56%
 
ASMB Assembly Biosciences, Inc.
13.39
-0.07%